Nephrology Therapeutics

1. Afinitor patent expiration

Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment
Nov, 2025

(1 year, 3 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-630) Oct 29, 2013
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-638) May 05, 2014
New Indication(I-650) Apr 26, 2015
New Indication(I-655) Jul 20, 2015
Pediatric Exclusivity(PED) Apr 29, 2018
Orphan Drug Exclusivity(ODE-11) May 05, 2018
Orphan Drug Exclusivity(ODE) Apr 26, 2019
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Dosage: TABLET

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

2. Anjeso patent expiration

Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Dosage: SOLUTION

More Information on Dosage

ANJESO family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Avycaz patent expiration

Treatment: Treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adult and pediatri...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(1 year, 5 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-738) Jun 22, 2019
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Patient Population(NPP) Dec 20, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Dosage: POWDER

More Information on Dosage

AVYCAZ family patents

Family Patents

4. Cabometyx patent expiration

Treatment: Treatment of advanced renal cell carcinoma; Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(2 months from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

5. Defitelio patent expiration

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

DEFITELIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 30, 2021
Orphan Drug Exclusivity(ODE-112) Mar 30, 2023
Orphan Drug Exclusivity(ODE) Mar 30, 2023

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

NCE-1 date: 30 March, 2020

Market Authorisation Date: 30 March, 2016

Dosage: SOLUTION

More Information on Dosage

DEFITELIO family patents

Family Patents

6. Feraheme patent expiration

Treatment: Method of treating patients needing an iron supplement

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8926947 COVIS Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Mar, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501158 COVIS Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Mar, 2020

(4 years ago)

US8591864 COVIS Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Mar, 2020

(4 years ago)

US6599498 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Mar, 2020

(4 years ago)

US7553479 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
Mar, 2020

(4 years ago)

US7871597 COVIS Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Mar, 2020

(4 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 30, 2012
New Indication(I-767) Feb 02, 2021

Drugs and Companies using FERUMOXYTOL ingredient

Market Authorisation Date: 30 June, 2009

Dosage: SOLUTION

How can I launch a generic of FERAHEME before it's drug patent expiration?
More Information on Dosage

FERAHEME family patents

Family Patents

7. Filspari patent expiration

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

FILSPARI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 17, 2028
Orphan Drug Exclusivity(ODE-389) Feb 17, 2030

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 17 February, 2027

Market Authorisation Date: 17 February, 2023

Dosage: TABLET

More Information on Dosage

FILSPARI family patents

Family Patents

8. Fosrenol patent expiration

Treatment: Reduction of serum phosphate in patients with end stage renal disease

FOSRENOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(a month from now)




Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 23 November, 2005

Dosage: TABLET, CHEWABLE

How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage

FOSRENOL family patents

Family Patents

9. Fotivda patent expiration

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS Use of tivozanib to treat subjects with refractory cancer
Nov, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2025

Market Authorisation Date: 10 March, 2021

Dosage: CAPSULE

More Information on Dosage

FOTIVDA family patents

Family Patents

10. Gelnique patent expiration

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449173 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 27, 2012

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Dosage: GEL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents

11. Gemtesa patent expiration

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Dosage: TABLET

More Information on Dosage

GEMTESA family patents

Family Patents

12. Glyxambi patent expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

GLYXAMBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 30, 2018
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Dosage: TABLET

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

13. Goprelto patent expiration

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 14 December, 2017

Dosage: SOLUTION

More Information on Dosage

GOPRELTO family patents

Family Patents

14. Injectafer patent expiration

Treatment: Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0...

INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11590097 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months ago)

US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months ago)

US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(8 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478502 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US8895612 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US7754702 AM REGENT Methods and compositions for administration of iron
Feb, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 25, 2016
New Strength(NS) Apr 28, 2024
New Patient Population(NPP) Nov 19, 2024
New Indication(I-915) May 31, 2026

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 28 April, 2021

Dosage: SOLUTION

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

15. Inlyta patent expiration

Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...

INLYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7141581 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Jun, 2020

(4 years ago)

US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(10 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2017

Drugs and Companies using AXITINIB ingredient

NCE-1 date: 28 January, 2016

Market Authorisation Date: 27 January, 2012

Dosage: TABLET

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

16. Inpefa patent expiration

Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7781577 LEXICON PHARMS INC Inhibitors of sodium glucose co-transporter 2 and methods of their use
May, 2028

(3 years from now)

US8476413 LEXICON PHARMS INC Sulfanyl-tetrahydropyran-based compounds and methods of their use
May, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2028

Drugs and Companies using SOTAGLIFLOZIN ingredient

NCE-1 date: 27 May, 2027

Market Authorisation Date: 26 May, 2023

Dosage: TABLET

More Information on Dosage

INPEFA family patents

Family Patents

17. Invokamet patent expiration

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Dosage: TABLET

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

18. Invokamet Xr patent expiration

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(8 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 20 September, 2016

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

19. Invokana patent expiration

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reductio...

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(8 months from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Indication(I-809) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Dosage: TABLET

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

20. Jardiance patent expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11666590 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-161) Jun 26, 2018
M(M-159) Jun 26, 2018
M(M-160) Jun 26, 2018
M(M-174) Mar 18, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
New Indication(I-869) Aug 18, 2024
M(M-82) Feb 24, 2025
Pediatric Exclusivity(PED) Dec 20, 2026
New Patient Population(NPP) Jun 20, 2026
New Indication(I-922) Sep 21, 2026

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Dosage: TABLET

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

21. Jesduvroq patent expiration

Treatment: Treatment of anemia due to chronic kidney disease

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(2 years from now)

US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 01, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 01 February, 2027

Market Authorisation Date: 01 February, 2023

Dosage: TABLET

More Information on Dosage

JESDUVROQ family patents

Family Patents

22. Korsuva patent expiration

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(3 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(3 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(3 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(3 years from now)

US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: 23 August, 2025

Market Authorisation Date: 23 August, 2021

Dosage: SOLUTION

More Information on Dosage

KORSUVA family patents

Family Patents

23. Livtencity patent expiration

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Dosage: TABLET

More Information on Dosage

LIVTENCITY family patents

Family Patents

24. Lonsurf patent expiration

Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf b...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2020
New Indication(I-794) Feb 22, 2022
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Dosage: TABLET

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents

25. Monoferric patent expiration

Treatment: Treatment of iron deficiency anemia (dia) in adults patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney dise...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8815301 PHARMACOSMOS AS Stable iron oligosaccharide compound
Aug, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633489 PHARMACOSMOS AS Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
Jun, 2036

(11 years from now)




Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Market Authorisation Date: 16 January, 2020

Dosage: SOLUTION

More Information on Dosage

MONOFERRIC family patents

Family Patents

26. Myrbetriq patent expiration

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...

MYRBETRIQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(8 months ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(8 months ago)

US7750029 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Dec, 2023

(6 months ago)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(4 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 28, 2017
New Indication(I-777) Apr 27, 2021
New Indication(I-855) Mar 25, 2024
Pediatric Exclusivity(PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

NCE-1 date: 26 September, 2023

Market Authorisation Date: 28 June, 2012

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

27. Nexavar patent expiration

Treatment: Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.

NEXAVAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity
Feb, 2023

(1 year, 5 months ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 20, 2012
New Indication(I-677) Nov 22, 2016
Orphan Drug Exclusivity(ODE-56) Nov 22, 2020

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Market Authorisation Date: 20 December, 2005

Dosage: TABLET

How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage

NEXAVAR family patents

Family Patents

28. Normocarb Hf 25 patent expiration

Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5945449 DIALYSIS SUPS Sterile bicarbonate concentrate
Oct, 2017

(6 years ago)

US7300674 DIALYSIS SUPS Sterile low bicarbonate dialysis concentrate solutions
Mar, 2023

(1 year, 4 months ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 26, 2013
More Information on Dosage

NORMOCARB HF 25 family patents

Family Patents

29. Normocarb Hf 35 patent expiration

Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5945449 DIALYSIS SUPS Sterile bicarbonate concentrate
Oct, 2017

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 26, 2013
More Information on Dosage

NORMOCARB HF 35 family patents

Family Patents

30. Numbrino patent expiration

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 OMNIVIUM PHARMS Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022
New Product(NP) Jan 10, 2023

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 10 January, 2020

Dosage: SOLUTION

More Information on Dosage

NUMBRINO family patents

Family Patents

31. Omontys patent expiration

Treatment: Treatment of anemia due to chronic kidney disease

Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 27, 2017

Drugs and Companies using PEGINESATIDE ACETATE ingredient

NCE-1 date: 27 March, 2016

Market Authorisation Date: 27 March, 2012

Dosage: SOLUTION

More Information on Dosage

OMONTYS family patents

Family Patents

32. Omontys Preservative Free patent expiration

Treatment: Treatment of anemia due to chronic kidney disease

Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)

US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(1 year, 10 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 27, 2017

Drugs and Companies using PEGINESATIDE ACETATE ingredient

NCE-1 date: 27 March, 2016

Market Authorisation Date: 27 March, 2012

Dosage: SOLUTION

More Information on Dosage

OMONTYS PRESERVATIVE FREE family patents

Family Patents

33. Opana Er patent expiration

Treatment: Dose modification for renal impairment

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808737 ENDO PHARMS Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Jun, 2027

(2 years from now)




Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 June, 2006

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OPANA ER family patents

Family Patents

34. Rayaldee patent expiration

Treatment: Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d; Use of sustained or extended release oral 25-hydroxy...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207149 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(3 years from now)

US9498486 EIRGEN Method for controlled release oral dosage of a vitamin D compound
Apr, 2028

(3 years from now)

US9408858 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(3 years from now)

US11801253 EIRGEN Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
Sep, 2030

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 17, 2019

Drugs and Companies using CALCIFEDIOL ingredient

Market Authorisation Date: 17 June, 2016

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

RAYALDEE family patents

Family Patents

35. Recarbrio patent expiration

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Dosage: POWDER

More Information on Dosage

RECARBRIO family patents

Family Patents

36. Recorlev patent expiration

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-385) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Dosage: TABLET

More Information on Dosage

RECORLEV family patents

Family Patents

37. Sunosi patent expiration

Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having mild, moderate, or severe renal impairment; Treatment of excessive daytime sleepiness associated with obstru...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US10940133 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839599 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839598 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850226 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850227 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850228 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11857528 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Dosage: TABLET

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

38. Synjardy patent expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...

SYNJARDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 26, 2018
M(M-174) Mar 18, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
New Patient Population(NPP) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Dosage: TABLET

How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage

SYNJARDY family patents

Family Patents

39. Synjardy Xr patent expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...

SYNJARDY XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019
M(M-296) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage

SYNJARDY XR family patents

Family Patents

40. Tarpeyo patent expiration

Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression; Reduction in loss of kidney function and reduction of proteinuri...

TARPEYO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932 CALLIDITAS Compositions for the oral delivery of corticosteroids
May, 2029

(4 years from now)

US11896719 CALLIDITAS Pharmaceutical compositions
Jan, 2043

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2024
Orphan Drug Exclusivity(ODE-389) Dec 15, 2028
Orphan Drug Exclusivity(ODE-464) Dec 20, 2030

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

TARPEYO family patents

Family Patents

41. Terlivaz patent expiration

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 14, 2027
Orphan Drug Exclusivity(ODE-406) Sep 14, 2029

Drugs and Companies using TERLIPRESSIN ACETATE ingredient

NCE-1 date: 14 September, 2026

Market Authorisation Date: 14 September, 2022

Dosage: POWDER

More Information on Dosage

TERLIVAZ family patents

Family Patents

42. Torisel patent expiration

Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

TORISEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-91) Apr 26, 2013
M(M-92) Jul 09, 2013
Pediatric Exclusivity(PED) Jan 09, 2014
Orphan Drug Exclusivity(ODE) May 30, 2014
M(M-61) May 30, 2015

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Dosage: SOLUTION

How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage

TORISEL family patents

Family Patents

43. Toviaz patent expiration

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

TOVIAZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384980 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7985772 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7855230 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US8338478 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(2 years ago)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2013
New Indication(I-861) Jun 17, 2024
Pediatric Exclusivity(PED) Dec 17, 2024

Drugs and Companies using FESOTERODINE FUMARATE ingredient

NCE-1 date: 18 December, 2023

Market Authorisation Date: 31 October, 2008

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage

TOVIAZ family patents

Family Patents

44. Tradjenta patent expiration

Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mel...

TRADJENTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-121) Aug 13, 2015
M(M-118) Aug 13, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Dosage: TABLET

How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage

TRADJENTA family patents

Family Patents

45. Trijardy Xr patent expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combinatio...

TRIJARDY XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(9 years from now)




Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

46. Ubrelvy patent expiration

Treatment: Acute treatment of migraine with or without aura in a patient with severe renal impairment

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857542 ABBVIE Treatment of migraine
Dec, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Dosage: TABLET

More Information on Dosage

UBRELVY family patents

Family Patents

47. Vabomere patent expiration

Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...

VABOMERE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183034 REMPEX Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(7 years from now)

US11007206 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US9694025 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US10561675 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(7 years from now)

US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 29, 2022
Generating Antibiotic Incentives Now(GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 29 August, 2026

Market Authorisation Date: 29 August, 2017

Dosage: POWDER

More Information on Dosage

VABOMERE family patents

Family Patents

48. Welireg patent expiration

Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...

Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)

US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 13, 2026
New Indication(I-931) Dec 14, 2026
Orphan Drug Exclusivity(ODE-364) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: 13 August, 2025

Market Authorisation Date: 13 August, 2021

Dosage: TABLET

More Information on Dosage

WELIREG family patents

Family Patents

49. Zerbaxa patent expiration

Treatment: Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease...

ZERBAXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(10 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019
Generating Antibiotic Incentives Now(GAIN) Dec 19, 2024
New Patient Population(NPP) Apr 21, 2025

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: 20 December, 2023

Market Authorisation Date: 19 December, 2014

Dosage: POWDER

More Information on Dosage

ZERBAXA family patents

Family Patents